BCL2 and cancer: The inhibition of mitochondrial bioenergetics promotes an early induction of intrinsic pathway (mitochondrial pathway) apoptosis by ABT-199 [62], a BCL2-selective inhibitor with cytotoxic action in several cancer cells [63], including triple-negative breast cancer cells [64].